Research programme: lung disorder therapeutics - OrPro Therapeutics

Drug Profile

Research programme: lung disorder therapeutics - OrPro Therapeutics

Alternative Names: ORP-100; recombinant modified human thioredoxin 1 - OrPro Therapeutics; Theradux

Latest Information Update: 30 Oct 2015

Price : $50

At a glance

  • Originator National Jewish Medical and Research Center
  • Developer OrPro Therapeutics
  • Class Recombinant proteins
  • Mechanism of Action Thioredoxin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cystic fibrosis; Lung disorders

Most Recent Events

  • 27 Oct 2015 OrPro Therapeutics receives patent allowance for recombinant modified human thioredoxin 1 in Cystic fibrosis and other Lung disorders in USA
  • 09 Oct 2014 Preclinical development in Cystic fibrosis is ongoing in USA
  • 31 Jul 2012 OrPro Therapeutics receives SBIR grant from the National Institutes of Health for the development of ORP 100, a lead candidate from OrPro's lung disorder therapeutics research programme, in Cystic fibrosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top